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Mitochondrial outer membrane permeabilization (MOMP) is the ultimate step in dozens of
lethal apoptotic signal transduction pathways which converge on mitochondria. One of the
representative systems proposed to be responsible for the MOMP is the mitochondrial
permeability transition pore (MPTP). Although the molecular composition of the MPTP
is not clearly understood, the MPTP attracts much interest as a promising target for
resolving two conundrums regarding cancer treatment: tumor selectivity and resistance
to treatment. The regulation of the MPTP is closely related to metabolic reprogramming
in cancer cells including mitochondrial alterations. Restoration of deregulated apoptotic
machinery in cancer cells by tumor-specific modulation of the MPTP could therefore be a
promising anti-cancer strategy. Currently, a number of MPTP-targeting agents are under
pre-clinical and clinical studies. Here, we reviewed the structure and regulation of the
MPTP as well as the current status of the development of promising MPTP-targeting
drugs.
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INTRODUCTION
Mitochondria are intracellular organelles essential not only for
energy production but also for various types of cell death includ-
ing apoptosis, necrosis, and mitotic catastrophy via mitochon-
drial outer membrane permeabilization (MOMP) (Martel et al.,
2012). Well-established central roles of mitochondria in intrin-
sic apoptotic pathway are involved in cytotoxic effect of many
of chemotherapeutic agents (Wenner, 2012). The mitochondria-
mediated intrinsic pathway is initiated by various stimuli, such
as high levels of cytoplasmic Ca2+, reactive oxygen species (ROS),
the activation of pro-apoptotic Bcl-2 family proteins, or UV dam-
age (Dejean et al., 2010; Shoshan-Barmatz and Ben-Hail, 2012).
In response to the various stimuli, mitochondria release apop-
togenic proteins like cytochrome c and Smac/Diablo, which are
consistently shown to be important for the propagation of fol-
lowing apoptotic cascades to the final destruction of the cell
(Youle and Strasser, 2008). It is generally believed that bioen-
ergetic and biosynthetic changes in cancer cells contributing to
the typical tumor characteristics of resistance are associated with
the alteration of mitochondria in cancer cells (Gogvadze et al.,
2009a). Accordingly, mitochondria have emerged as effective tar-
gets for novel anti-cancer agents, so called, mitocans (Neuzil et al.,
2006).
Release of apoptogenic protein, particularly cytochrome c, is
considered “a point of no return,” resulting in apoptotic cell death
(Gogvadze et al., 2009a). This commitment step of apoptosis,
release of cytochrome c from the intermembrane space, seems to
largely depend on MOMP. Moreover, as apoptotic machinery of
cancer cell mitochondria is structurally and functionally differ-
ent from that of their normal counterparts (Fulda et al., 2010),
mitochondrial-targeted agents are expected to have a tumor selec-
tivity. Although the mechanisms underlying MOMP remain to
be determined, it appears to be clear that various kinds of pro-
tein complexes on mitochondrial membranes, including Bcl-2
family proteins, orchestrate the final apoptotic responses such
as DNA fragmentation and blebbing of the plasma membrane
(Dejean et al., 2010). Among them, the mitochondrial perme-
ability transition pore (MPTP) is thought as the most viable
model of mitochondrial channels which account for the MOMP
(Mathupala et al., 2006).
Here, we provide a brief review of the structure and regu-
lation of the MPTP, followed by comprehensive review of the
developmental status of promising MPTP-targeting drugs.
THE CONCEPT OF THE MITOCHONDRIAL PERMEABILITY
TRANSITION PORE
Mitochondrial permeability transition (MPT) is the sudden per-
meabilization of the inner mitochondrial membrane (IMM) in
response to a noxious stimulus such as oxidative stress, Ca2+
overload, hypoxia, and cytotoxic drugs (McCommis and Baines,
2012). MPT is thought to occur after the opening of the MPT
pore (MPTP), although the composition of MPTP is not clearly
understood yet (Nakagawa et al., 2005). The opening of MPTP
causes depolarization of the IMM and swelling of the matrix
space, which results in nonspecific rupture of the outer mito-
chondrial membrane (OMM) due to larger surface area of the
IMM than the OMM (Kinnally and Antonsson, 2007). Despite
much debate on the role of MPTP in the mitochondrial pathway
of apoptosis, there are several lines of evidence for the structure
and regulation of MPTP in apoptosis.
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STRUCTURE OF THE MPTP
Despite accumulating evidence for the molecular constituents
of the MPTP, the proteins responsible for pore formation have
not been fully identified. Traditionally, MPTP has been regarded
as a multimeric complex, which putatively consists of the volt-
age dependent anion channel (VDAC) in the OMM, the ade-
nine nucleotide translocase (ANT) in the IMM, cyclophilin D
(CyP-D)—a mitochondrial matrix protein that exhibits peptidyl-
prolyl cis-trans-isomerase activity, and some other proteins such
as hexokinase (HK) (Mathupala et al., 2006; Gogvadze et al.,
2009a). However, several studies reported that none of them
might be part of the pore, even if ANT and CyP-D were MPTP
regulators (Kokoszka et al., 2004; Baines et al., 2005, 2007).
VDAC AS A PART OF THE MPTP
Because VDAC is the most abundant protein in the OMM,
VDAC has long been believed to be a potential OMM compo-
nent of the MPTP (Figure 1A) (McCommis and Baines, 2012).
As a part of the MPTP, VDAC was thought to cause the
release of cytochrome c indirectly through the swelling and rup-
ture of OMM. The electrical conductance properties of VDAC
were similar to those of the MPTP (Szabo et al., 1993), and
the MPTP and VDAC shared the stimuli, such as ROS, Ca2+,
voltage, adenine nucleotide, and pH (Halestrap et al., 2004;
Di Lisa et al., 2007). Moreover, previous experiments using
anti-VDAC monoclonal antibodies provided additional sup-
porting evidence that the MPT in isolated mitochondria was
FIGURE 1 | Proposed models for mechanism of the mitochondrial outer
membrane permeabilization (MOMP). (A) VDAC is the OMM component
of the MPTP complex. In this model, pro-apoptotic proteins (Bax and Bad)
interact with VDAC to accelerate its opening, whereas Bcl-XL binds to VDAC
directly to close it. VDAC can cause cyt c release indirectly through the
swelling and rupture of the OMM. However, this model has problems of
relatively small pore size and dispensability of VDAC. (B) In an anti-apoptotic
state, anti-apoptotic molecules (HK II and Bcl-XL) bind to VDAC and keep it in
open configuration with low-conductance for the exchange of adenine
nucleotides, which maintains OMM integrity. HK II competes with Bcl-XL for
binding site of VDAC. In a pro-apoptotic state, HK II detachment from VDAC
promotes binding of Bcl-XL to VDAC, releasing Bax from Bcl-XL. Free Bax
interacts with Bax/Bak to form pore structures for the release of cyt c. Bad
interacts with Bcl-XL on Bcl-XL/Bax and Bcl-XL/VDAC, which release Bax from
Bcl-XL/Bax heterodimer to form Bax/Bak and displace Bcl-XL from VDAC to
be sensitized to Ca2+ , respectively. In this model, tBid was shown to induce
VDAC closure, reducing adenine nucleotide exchange and creating
mitochondrial dysfunction, which may cause the MOMP.
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prevented by blocking VDAC’s channel activity (Zheng et al.,
2004).
Nevertheless, the concept of this model has been discredited
because of several conflicting evidence. Firstly, the estimated pore
size of VDAC, 2.2 ± 0.05 nm (Pavlov et al., 2001), does not seem
to be large enough for the passage of cytochrome c, of which the
diameter is up to 3 nm (Kinnally and Antonsson, 2007). Secondly,
the closure of VDACmay not correspond to the closure of MPTP.
It was shown that treatment of isolated mitochondria with G3139,
an 18-mer phosphorothioate blocker of VDAC, resulted in VDAC
closure, which caused an accumulation of intramitochondrial
ROS and accelerated onset of the MPT (Tikunov et al., 2010).
Rostovtseva et al. reported that the VDAC channel, even in the
closed state, was still large enough to pass solutes up to 1.5 kDa in
size, which indicated that the closed state of VDAC might be the
same as the open state of the MPTP (Rostovtseva et al., 2005).
They also concluded that VDAC did not form channels that
mediate the flux of proteins through membranes. Lastly, recent
experiment with VDAC-deficient null mitochondria showed the
maintenance of MPT responses, suggesting that VDAC might be
dispensable for MPT and at least not an essential component of
the MPTP (Baines et al., 2007).
VDAC AS A SEPARATE PORE FOR ADENINE NUCLEOTIDE EXCHANGE
Several competing models have been proposed to overcome the
weaknesses of aforementioned model (Shimizu et al., 2000; Zalk
et al., 2005; Shoshan-Barmatz and Ben-Hail, 2012). At this time,
the most viable model for the MPTP might be VDAC as a sepa-
rate channel for exchange of mitochondrial metabolites, such as
adenine nucleotide (Figure 1B) (McCommis and Baines, 2012).
The concept of this new model fits quite well into the MPTP
paradigm, even though lots of mechanisms are to be determined.
The exchange of metabolites across the OMM is crucial for
coupled cellular respiration (Vander Heiden et al., 2001). In
a pro-apoptotic state, pro-apoptotic modulators such as tBid
were found to close VDAC, which inhibited metabolite exchange
between mitochondria and cytosol. The resultant build-up of the
metabolites in the intermembrane spacemay causemitochondrial
dysfunction, leading to the MOMP and the release of cytochrome
c (Rostovtseva et al., 2004). However, the mechanisms of how
mitochondrial dysfunction can induce the MOMP and specific
OMM route for cytochrome c are still unknown (McCommis
and Baines, 2012). On the contrary, in an anti-apoptotic state,
anti-apoptotic agents such as HK and Bcl-XL have been shown
to bind to VDAC and keep it open configuration, sustaining the
exchange of the metabolic anions including ATP/ADP (Vander
Heiden et al., 2001; Mathupala et al., 2006). It has been proposed
that the maintenance of a low conductance state of VDAC may
prevent the MOMP (Fulda et al., 2010).
REGULATION OF THE MPTP
HK II-VDAC INTERACTION
HK catalyzes the first step of the glycolytic pathway where glu-
cose is phosphorylated to glucose-6-phosphate (Mathupala et al.,
2006). Among four isoforms of HK, HK II is known to be
overexpressed in most neoplastic cells where it contributes to
the proliferation and survival of tumor cells through enhancing
aerobic glycolysis, i.e., Warburg effect. In addition to providing
the precursor for glycolysis and biosynthesis of key metabolites,
mitochondrial HK II is believed to play an important role in
maintaining the OMM integrity through the interaction with
VDAC and inhibiting mitochondrial-mediated apoptosis.
Binding of HK II to VDAC may inhibit the MPTP forma-
tion in at least two ways (Mathupala et al., 2006). Firstly, HK II
binding could change the conformation of VDAC, which might
in turn alter the conformation of ANT that is not conducive for
formation of a MPTP. One of the possible roles of VDAC might
be to keep the ANT in the c-conformation, in which the conver-
sion of the ANT into the MPTP by Ca2+ is facilitated (Vyssokikh
and Brdiczka, 2003). The preference of VDAC-bound HK II for
mitochondria-derived ATP suggests that HK II binding to VDAC
may induce a structural modification of VDAC for the passage of
ATP (Vyssokikh and Brdiczka, 2003). Secondly, VDAC occupied
by HK II is shown to prevent Bax and other pro-apoptotic pro-
teins binding to it, which in turn prevents their oligomerization
necessary for activation of the MPTP (Mathupala et al., 2006).
The importance of HK II-VDAC interaction as a key compo-
nent of the regulation of the cellular apoptotic signaling cascades
is further supported by the research of Shulga et al. (2009). They
used the fifteen amino acid N-terminal peptide of HK II (N-HK
II) which competes with the intact protein for binding to VDAC.
Treatment of HCT-116 colon cancer cells with N-HK II peptide
was found to re-localize HK II from the mitochondria to the
cytosol. Furthermore, treatment of HCT-116 cells with cisplatin
in combination with the N-HK II peptide was shown to cause
a synergistic enhancement of cytotoxicity. These results suggest
that detachment of HK II from the mitochondria might sensitize
the mitochondria to the cisplatin-induced cell damage, leading to
much enhanced cytotoxicity (Shulga et al., 2009).
Akt, also known as protein kinase B and the potent effector
of anti-apoptotic stimuli in tumors, is another potent regula-
tor of HK II-VDAC binding (Mathupala et al., 2006). Akt can
directly phosphorylate HK II to enhance binding of HK II to the
mitochondria (Elstrom et al., 2004).
Bcl-2 FAMILY PROTEINS
Another critical regulation of the cellular apoptosis via the MPTP
is the balance between pro- and anti-apoptotic Bcl-2 family
proteins (Gogvadze et al., 2009b). Bcl-2 family proteins have
classically been comprised of three groups: anti-apoptotic mul-
tidomain proteins (Bcl-2, Bcl-XL, Bcl-W, Mcl-1, and A1A); pro-
apoptotic multidomain proteins (Bax and Bak); pro-apoptotic
BH3-only proteins (Bim, Bid, Bad, Bik, Hrk, Puma, and Noxa)
(Kroemer et al., 2007). It is generally accepted that BH3-only pro-
teins can induce apoptosis primarily by inhibiting anti-apoptotic
Bcl-2 family proteins and derepressing Bax and Bak. For example,
Bad may interact with Bcl-XL and release Bax from Bcl-XL/Bax
heterodimers (Willis et al., 2005). In addition, Roy et al. suggested
a Bax/Bak-independent mechanism of Bad to sensitize the open-
ing of the MPTP, which indicated that dephosphorylated Bad
could interact with Bcl-XL and displacement it from VDAC that
led to the sensitization of the MPTP to Ca2+ (Roy et al., 2009).
Whereas Bax is mostly cytosolic, Bak is known to reside on the
OMM under normal circumstances. Although how Bax and Bak
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induce the MOMP remains elusive, it seems to be clear that Bax
coalescence through translocation to the OMM and Bak acti-
vation promote mitochondrial fragmentation and cytochrome
c release (Youle and Strasser, 2008).
Regarding HK II-VDAC interaction, HK II may compete with
Bcl-XL for VDAC binding site. Thus, HK II binding to VDAC
releases Bcl-XL from VDAC and facilitates binding of Bcl-XL
to Bax, which prevents Bax-Bax oligomerization or Bax-Bak
interaction. However, HK II detachment from VDAC, for exam-
ple, through phosphorylation of VDAC by glycogen synthase
kinase 3β (GSK 3β), promotes binding of Bcl-XL to VDAC, leav-
ing Bax free from Bcl-XL. Free Bax interacts with Bak and/or
Bax to form pore structures for the release of cytochrome c
(Pastorino and Hoek, 2008). Interestingly, though all VDAC in
this review indicate VDAC 1, Cheng et al. reported the dis-
tinct role of VDAC 2, a VDAC isoform present in low abun-
dance that interacts specifically with the inactive conformer
of Bak (Cheng et al., 2003). They showed cells deficient in
VDAC 2, but not cells lacking VDAC 1, exhibited increased Bak
oligomerization and were more susceptible to apoptotic death.
In addition, they also indicated that BH3-only proteins dis-
placed VDAC 2 from Bak, enabling Bak-Bak interaction and
apoptosis.
CyP-D AS A REGULATOR OF HK II BIDING TO VDAC
Several studies have shown that CyP-D is up-regulated in many
human tumors and can function as an apoptosis repressor (Lin
and Lechleiter, 2002; Schubert and Grimm, 2004). Growing num-
ber of evidence demonstrated that the anti-apoptotic regulation
of CyP-D might be associated with the stabilization of HK II
binding to mitochondria (Machida et al., 2006; Chiara et al.,
2008). Inactivation of CyP-D with cyclosporine A or knock-
down of the expression using siRNA was shown to release HK
II from mitochondria. Because CyP-D is a mitochondrial matrix
protein, an intermediate in the IMM between the OMM and
matrix is necessary for its modulation of HK II binding to
VDAC. ANT in the IMM could play this intermediation role
(Chevrollier et al., 2005). However, Chiara et al. showed the
opposing pro-apoptotic role of CyP-D in apoptosis (Chiara et al.,
2008). They demonstrated that HK II detachment-triggering
apoptosis might be associated with a disruption of the inter-
action of CyP-D with ANT. Furthermore, inhibition of CyP-D
was shown to prevent the onset of the MPTP. Further inves-
tigation is needed to fully understand the role of CyP-D in
apoptosis.
ERK/GSK3/CyP-D TRANSDUCTION PATHWAY
Recently, ERK/GSK3/CyP-D was proposed to be a transduction
axis which was responsible for the regulation of the MPTP open-
ing in tumor cells (Rasola et al., 2010; Traba et al., 2012). ERK
was reported to be constitutively activated in mitochondria of
several cancer cell types (Rasola et al., 2010). Recent work indi-
cated that ERK activation prevented the release of apoptogenic
proteins whereas the inhibition of ERK activity induced profound
depletion in cellular ATP coincident with a loss of mitochondrial
membrane potential (Monick et al., 2008). In addition, ERK acti-
vation was shown to inhibit GSK3-dependent phosphorylation
of the MPTP regulator CyP-D and render cancer cells more
refractory to the MPTP opening (Rasola et al., 2010).
TARGETING CANDIDATES
Again, cytochrome c release is the commitment step of
mitochondria-mediated apoptosis. Therefore, the manipula-
tion of mitochondrial channels responsible for the release of
cytochrome c from intermembrane space could provide a win-
dow of opportunity for efficient and selective anti-cancer therapy.
A variety of compounds that act via mitochondria, so called,
mitocans, were shown to destabilize mitochondria and cause
apoptosis in selected cancer cells (Ralph and Neuzil, 2009). Many
of MPTP-targeting mitocans are currently under various stages of
clinical development (Table 1).
MODULATORS OF THE Bcl-2 FAMILY PROTEINS
ABT-737, ABT-263
The susceptibility of cancer cells to undergo apoptosis via
MPTP is often determined by the balance between pro-apoptotic
and anti-apoptotic Bcl-2 family proteins. BH3 mimetics, small
molecules that have close structural or functional similarity to
BH3-only proteins, may shift the balance toward pro-apoptotic
members, initiating MOMP-dependent apoptosis (Fulda et al.,
2010).
One of best characterized BH3 mimetics, ABT-737, binds to
Bcl-2, Bcl-XL, and Bcl-W, releasing sequestered pro-apoptotic
proteins and inducing cell death through the intrinsic apoptotic
pathway. For example, ABT-737 can bind to interfere with the
binding of Bcl-2 with pro-apoptotic proteins, releasing free form
of pro-apoptotic proteins. Increased expression of Bcl-2 in tumor
cells indicates that these cells might be “primed to die” because
of the increased amount of sequestered pro-apoptotic proteins
(Dejean et al., 2010). However, many cancers with overexpres-
sion of Bcl-2 exhibit a resistance to mitochondrial apoptotic cell
death (Certo et al., 2006). This means that ABT-737 may act as an
apoptosis sensitizer synergistically with chemotherapeutic agents
to reverse the chemoresistance and selectively kill these cancer
cells without serious toxicity (Hann et al., 2008; Kutuk and Letai,
2008). Nonetheless, Van Delft et al. showed the refractoriness of
many types of cancer cells to ABT-737 possibly due to ABT-737’s
inability to target another pro-survival protein, Mcl-1(Van Delft
et al., 2006). The expected advantage of targeting of both the
Bcl-2 and Mcl-1 mechanisms of apoptosis resistance was demon-
strated in various types of cancers (Bray et al., 2009; Zhang et al.,
2012). To improve the clinical compliance of ABT-737, an orally
available derivative, ABT-263, has been generated and now under
investigation in various clinical trials commonly in combination
with conventional chemotherapeutic agents or other molecular
targeted agents in both solid and blood malignancies (Wilson
et al., 2010; Rudin et al., 2012).
AT-101 (gossypol)
Gossypol, a natural phenolic compound in cotton plants, is
shown to inhibit Bcl-2, Bcl-XL, Bcl-W, Mcl-1 (Azmi and
Mohammad, 2009). Gossypol showed clinical activity in a phase
I trial against prostate cancer and currently under investigation
(Liu et al., 2009). Although gossypol exhibited a possible survival
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Table 1 | Summary of the developmental status of anti-cancer agents targeting mitochondrial apoptotic machinery.
Agent Target or mode of action Phase of clinical development References
MODULATORS OF THE Bcl-2 FAMILY PROTEINS
ABT-263 Bcl-2, Bcl-XL, Bcl-W Phase II Rudin et al., 2012
ABT-737 Bcl-2, Bcl-XL, Bcl-W Pre-clinical (in vitro and in vivo) Mason et al., 2008
AT-101 (gossypol) Bcl-2, Bcl-XL, Bcl-W, Mcl-1 Phase II Van Poznak et al., 2001
GX15-070 (obatoclax) Bcl-2, Bcl-XL, Bcl-W, Mcl-1 Phase II Parikh et al., 2010
HA14-1 Bcl-2 Pre-clinical (in vitro and in vivo) Simonin et al., 2009
G3139 (oblimersen) Bcl-2 mRNA antisense Phase III O’Brien et al., 2007
METABOLIC INHIBITORS
Methyl jasmonate HK II-VDAC interaction Pre-clinical (in vitro and in vivo) Goldin et al., 2008
3-Bromopyruvate HK II-VDAC interaction Pre-clinical (in vitro and in vivo) Chen et al., 2009
HK II peptide HK II-VDAC interaction Pre-clinical (in vitro) Chiara et al., 2008
VDAC AND/OR ANT-TARGETING AGENTS
Arsenite trioxide (As2O3) ANT ligand, ROS production Phase IV Powell et al., 2010
Lonidamine ANT ligand Phase IV Di Cosimo et al., 2003;
Oudard et al., 2003
Clodronate ANT inhibitor Phase III Lehenkari et al., 2002
GSAO ANT cross linker Pre-clinical (in vitro and in vivo) Don et al., 2003
FNQs VDAC1 Pre-clinical (in vitro and in vivo) Simamura et al., 2006
Erastin VDAC2 and VDAC3 Phase I NCT00528047
ROS REGULATORS
Motexafin gadolinium ROS production, Akt Phase III Mehta et al., 2009
Bismaleimido-hexane ANT thiol oxidation Pre-clinical (in vitro) Palmeira and Wallace, 1997
Dithiodipyridine ANT thiol oxidation Pre-clinical (in vitro and in vivo) Lifson et al., 2004
RETINOIDS
All-trans-retinoid acid ANT ligand Pre-clinical (in vitro and in vivo) Notario et al., 2003
CD437 MPTP Pre-clinical (in vitro) Marchetti et al., 1999;
Belzacq et al., 2001
NATURAL COMPOUNDS
Resveratrol F1-ATPase Phase II Gledhill et al., 2007
Curcumin Bax, Bcl-2, Bcl-XL, NF-κB Phase III Carroll et al., 2011
Betulinic acid MPTP Pre-clinical (in vitro) Fulda et al., 1997
Berberine ANT ligand Pre-clinical (in vitro and in vivo) Pereira et al., 2008
α-tocopheryl succinate Bax, ubiquinone-binding sites
in respiratory complex II
Pre-clinical (in vitro and in vivo) Dong et al., 2008
Honokiol Cyclophilin D Pre-clinical (in vitro and in vivo) Arora et al., 2012
ANT, adenine nucleotide translocase; GSAO, 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide; CD437, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene car-
boxylic acid; HA14-1, 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate;HK, hexokinase;Mcl-1, myeloid cell leukemia sequence 1; MPTP,
mitochondrial permeability transition pore; ROS, reactive oxygen species; VDAC, voltage-dependent anion channel. Modified and adapted by permission from Fulda
et al. (2010) and Barbosa et al. (2012).
benefit in randomized phase II study for second-line treatment
of non-small cell lung cancer in combination with docetaxel
(Ready et al., 2011), Baggstrom et al. failed to show the efficacy
of gossypol in patients with recurrent chemosensitive small cell
lung cancer (Baggstrom et al., 2011).
Gx15-070 (obatoclax)
Obatoclax, a small molecule indole bipyrrole compound, also
inhibits Bcl-2, Bcl-XL, Bcl-W, Mcl-1 (O’Brien et al., 2009).
Obatoclax was demonstrated to efficiently disrupt the interaction
between Bak and Mcl-1, overcoming the mcl-1 dependent resis-
tance to the proteasome inhibitor bortezomib against multiple
myeloma (Nguyen et al., 2007).
HA14-1
HA14-1, an organic compound, was shown to specifically inhibit
Bcl-2 (Wang et al., 2000). Although HA14-1 was reported
to increase the sensitivity of cancer cells to chemotherapy or
radiotherapy, the clinical trials with HA14-1 have not yet been
initiated (Manero et al., 2006).
G3139 (oblimersen)
Oblimersen, an 18-mer phosphorothioate Bcl-2 mRNA anti-
sense, anneals to the initiation codon region of Bcl-2 mRNA,
thereby inhibiting Bcl-2 biosynthesis (Fulda et al., 2010).
Oblimersen was also shown to directly bind and reduce the
channel conductance of VDAC (Tan et al., 2007).
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DISRUPTORS OF THE HK II-VDAC INTERACTION
HK II-VDAC interactions are now believed to be crucial also
for promoting cancer survival via modulation of signaling events
related to apoptosis. Considering that HK II is frequently over-
expressed in cancers and HK-VDAC binding is tighter in cancer
cells than that in normal counterparts, disruption of the HK II-
VDAC interaction could offer another basis for a novel selective
anti-cancer strategy (Pastorino et al., 2005).
Methyl jasmonate
Methyl jasmonate, a plant-derived small molecule, is shown to
exhibit anti-cancer activity via specific binding to HK II and dis-
rupting the HK II-VDAC interaction, thereby favoring MOMP in
cancer cell lines (Goldin et al., 2008). Goldin et al. also reported
that methyl jasmonate could have cancer-selective effects because
many types of cancer cells overexpressed HK II with excessive
binding to mitochondria compared with their normal counter-
part. Actually there are two additional anti-cancer mechanisms of
methyl jasmonate: induction of severe ATP depletion in cancer
cells via mitochondrial perturbation and induction of apoptosis
in lung carcinoma cells via the generation of hydrogen perox-
ide and pro-apoptotic Bcl-2 family proteins (Cohen and Flescher,
2009).
3-bromopyruvate
The pyruvate analog, 3-bromopyruvate, is an alkylating agent and
a potent inhibitor of glycolysis (Ganapathy-Kanniappan et al.,
2010). 3-Bromopyruvate is known to inhibit energy metabolism
of glycolysis-dependent tumor cells and trigger cell death pre-
sumably through depletion of cellular ATP (Kim et al., 2007).
Moreover, 3-bromopyruvate was recently shown to cause a cova-
lent modification of HK II protein and directly trigger its dissoci-
ation from mitochondria, leading to specific release of apoptosis
inducing factor (AIF) from the mitochondria to cytosol and
eventual cell death (Chen et al., 2009).
Clotrimazole
Clotrimazole was shown to induce HK II detachment from
mitochondria of many cancer cells and prompt a concentration-
dependent cell death (Pastorino et al., 2002; Machida et al.,
2006). However, the toxic effects of clotrimazole onmitochondria
appeared to be through the inhibition of mitochondrial respira-
tion by binding to a molecular target other than HK II (Chiara
et al., 2008). Therefore, the non-specific toxic effects of clotri-
mazole are likely to cause significant side effects, which might
discourage its clinical use as an anti-cancer drug.
HK II-based peptides
As mentioned above, newly designed oligopeptides correspond-
ing to the N-terminal hydrophobic domain of HK II were shown
to compete with the intact HK II for binding to VDAC and effec-
tively displace HK II from VDAC (Pastorino et al., 2002). Unlike
clotrimazole, the HK II-based peptide is expected to exhibit
tumor cell specificity because it does not affect mitochondrial
respiration (Chiara et al., 2008). Clinical trials for HK II-based
peptide are warranted.
ANT INHIBITORS
Arsenite trioxide (As2O3)
Arsenite is recently proved to be highly effective in treating acute
promyelocytic leukemia (APL) (Powell et al., 2010). One of the
key mechanisms proposed was an apoptotic effect via the open-
ing of the MPTP (Larochette et al., 1999). Arsenite was shown to
dissipate the mitochondrial membrane potential, while the pro-
apoptotic effect of arsenite was inhibited by Bcl-2 overexpression
(Larochette et al., 1999). It has been found that ANT is one of
the targets of arsenite within MPTP (Belzacq et al., 2001). Cell
free systems of apoptosis have revealed that arsenite induces the
permeabilization of ANT proteoliposomes and requires mito-
chondria to trigger nuclear apoptosis in vitro (Belzacq et al.,
2001).
Lonidamine
Lonidamine, an indazole carboxylate, has been demonstrated
to inhibit ANT and trigger mitochondria-mediated apoptosis
(Fulda et al., 2010). It was found that lonidamine induced the
permeabilization of liposomes containing ANT, while had no
effect on protein-free liposomes (Belzacq et al., 2001). Despite
the cytostatic effect in recurrent glioblastoma multiforme and
the additional improvement of response rate in epirubicin treat-
ment for the patients with advanced breast cancer, lonidamine
was shown to be toxic to non-tumor tissues, for example,
causing hepatotoxicity (Barbosa et al., 2012). Nevertheless,
lonidamine is currently undergoing phase III/IV clinical trials
(Table 1).
Clodronate
Clodranate, a nitrogen-free bisphosphonate, can also act as com-
petitive ANT inhibitor, leading to the dissipation of the mito-
chondrial membrane potential and apoptosis (Fulda et al., 2010).
Although the underlying mechanisms are still elusive, it was
shown that the addition of clodronate to postoperative adjuvant
therapy in breast cancer patients improved the overall survival
outcomes (Diel et al., 2008).
4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO)
GSAO was shown to cross-link cysteine residues of ANT
and inhibit the exchange of ATP/ADP through ANT, lead-
ing to mitochondrial membrane depolarization and apopto-
sis (Don et al., 2003). Interestingly, GSAO seems to be a
promising anti-cancer drug since GSAO is shown to inhibit
tumor angiogenesis by selectively targeting mitochondria in
proliferating endothelial cells presumably due to the higher
amounts of mitochondria in endothelial cells than in tumor cells
(Don et al., 2003).
Furanonaphthoquinones (FNQs)
FNQs, isolated from the inner bark of tropical trees, were
shown to target VDAC1 (Simamura et al., 2006). FNQs
might induce apoptosis via the NADH-dependent production
of ROS, leading to collapse of the mitochondrial membrane
potential and caspase 9 activation (Simamura et al., 2006).
The ROS production of FNQs was increased upon VDAC1
overexpression.
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Erastin
Erastin was shown to bind VDAC2 and 3 to induce NADH-
dependent oxidative cell death by inducing RAS-RAF-MEK path-
way (Pathania et al., 2009). The erastin analogue, PRLX 93936, is
currently undergoing phase I clinical trial (Table 1).
All-trans-retinoid acid
All-trans-retinoid acid and retinoid-related compounds,
CD437 (6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene
carboxylic acid) are well known to induce clinical remission
in patients with APL (Slack and Rusiniak, 2000). In addition
to the stimulation of the expression of retinoic acid receptor-
responsive genes, these retinoids was recently shown to trigger
ANT-dependent MPT (Belzacq et al., 2001; Notario et al., 2003).
ROS REGULATORS
Motexafin gadolinium
Motexafin gadolinium (MGd) is an expanded porphyrin which
displays an elevated oxidizing potential, thereby triggering excess
generation of ROS (Fulda et al., 2010). MGd is known as a radio-
and chemo-sensitizer because of the preferential accumulation in
cancer cells (Magda andMiller, 2006). Intriguingly, pro-apoptotic
effect of MGd was shown to be enhanced by combining it with
Akt phosphorylation inhibitors such as celecoxib or docetaxel
(Ramos et al., 2006). It suggests that modulation of the lev-
els of phosphorylated Akt may be one of the modes of action
of MGd and the synergistic cytotoxicity can be induced by the
combination of MGd with inhibitors of Akt phosphorylation
(Ramos et al., 2006).
Thiol crosslinking agents
Bismaleimido-hexane (BMH) and dithiodipyridine (DTDP) can
cause thiol oxidation of a critical cysteine residue (Cys 56) of
ANT, through which BMH and DTDP may induce MOMP and
cell death irrespective of the expression level of Bcl-2 (Costantini
et al., 2000). Moreover, recombinant Bcl-2 was found to fail
to prevent thiol modification of ANT, suggesting that both
thiol crosslinkers could bypass Bcl-2-mediated cytoprotection
(Costantini et al., 2000).
NATURAL COMPOUNDS
Resveratrol
Resveratrol, a polyphenolic compound from grapes and wine,
can inhibit mitochondrial ATP synthesis and trigger MOMP
(Fulda et al., 2010). Recently, one of the synthetic resveratrol
analogues, HS-1793, was shown to induce collapse of mito-
chondrial membrane potential and cytochrome c release in
murine breast cancer cell lines (Kim et al., 2012). In addi-
tion, HS-1793 was also demonstrated to circumvent Bcl-2-
mediated apoptosis resistance in leukemia cells (Jeong et al.,
2009). Resveratrol is currently undergoing phase I/II clinical trials
(Table 1).
Curcumin
Curcumin is a major constituent of turmeric powder from the
plant Curcuma longa. Among several anti-cancer mechanisms of
curcumin are the modulation of Bcl-2 family proteins and cellular
ROS, inhibition of the NF-κB survival pathway, and inhibition of
cyclooxygenase-2 (Divya and Pillai, 2006; Singh and Khar, 2006;
Madden et al., 2009; Pinlaor et al., 2009; Shehzad et al., 2010).
Curcumin is currently undergoing phase II/III clinical trials.
Betulinic acid
Betulinic acid, a natural pentacyclic triterpenoid of the lupane
class, is known to trigger mitochondrial apoptosis in cancer cells
(Fulda et al., 2010). Betulinic acid not only directly triggers
MOMP but also modulates Bcl-2 family proteins (Fulda et al.,
1997; Selzer et al., 2002).
Berberine
Berberine, an alkaloid derived from plants of the Berberidaceae
family, has been shown to exert direct effects on mitochon-
dria, including the interaction with ANT (Pereira et al., 2008).
Several other mechanisms underlying the induction of apoptosis
by berberine includes the alterations in the Bcl-2/Bax ratio, ROS
production, a decrease in mitochondrial membrane potential,
and cytochrome c release (Fulda et al., 2010).
α-Tocopheryl succinate (α-TOS)
α-TOS, a vitamin E analogue, competes with ubiquinone in
binding to Q sites of respiratory complex II, which results
in the displacement of ubiquinone from complex II, disrupts
the electron flux, and consequently generating ROS (Dong
et al., 2008). In the cytosol, ROS catalyze the formation of
disulfide bridges between Bax monomers, causing a confor-
mational change for dimerization which is followed by Bax
translocation to the OMM to form channels (Neuzil et al.,
2006). In addition, α-TOS binds to Bcl-2 and Bcl-XL on the
OMM to prevent them trapping Bax, allowing free Bax to
form OMM channels (Neuzil et al., 2006). The same group
recently proposed another mechanism of α-TOS-induced apop-
tosis, which involved Noxa-Bak axis (Prochazka et al., 2010).
The tumor selectivity of α-TOS due to its ester structure
and preferential triggering apoptosis in proliferating endothelial
cells form very promising in vitro data, which warrant fur-
ther clinical trials with α-TOS (Neuzil et al., 2001; Dong et al.,
2007).
Honokiol
Honokiol is a small molecule polyphenol isolated from the genus
Magnolia (Fried and Arbiser, 2009). Recently, the antiangiogenic
and antitumor activities of honokiol have been reported in pre-
clinical models. Major mechanisms of action of honokiol include
the induction of CyP-D, potentiating the MPTP. Importantly,
honokiol-induced CyP-D-regulated cell death was shown to be
able to overcome Bcl-2 and Bcl-XL-mediated apoptotic resistance
in primary human leukemia cells (Li et al., 2007). These promis-
ing preclinical data may warrant the development of clinical trials
of honokiol.
INHIBITION OF ERK/GSK3/CyP-D TRANSDUCTION PATHWAY
Again, GSK3 plays a role in the opening of the MPTP through
the phosphorylation of CyP-D. In 206 osteosarcoma ρ◦ cells with
an extreme Warburg phenotype, constitutively active ERK was
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shown to oppose this signaling by phosphorylating and inhibit-
ing GSK3 (Masgras et al., 2012). Starvation through serum and
glucose depletion resulted in ERK inhibition and GSK3 activa-
tion in ρ◦ cells. Through the activation of ERK/GSK3/CyP-D
transduction pathway, starvation could induce 206 ρ◦ cells
to undergo a rapid mitochondrial depolarization (Masgras
et al., 2012). Therefore, starvation might be another way
to induce MPTP opening in the glycolysis-dependent tumor
cells.
CONCLUSIONS
Mitochondria have pivotal opposing roles in energy generation
for cell survival and cytochrome c release for apoptotic cell death.
Although the concept of the MPTP is still evolving, mount-
ing evidence indicates that the MPTP is directly responsible for
cytochrome c release, leading to apoptotic cell death. Targeting
the MPTP for cancer treatment has two advantages: tumor
specificity and bypass of the resistance mechanisms. Metabolic
reprogramming and mitochondrial alterations in cancer cells
could provide important clues for developing tumor-specific
anti-cancer agents. MOMP finally occurs as a consequence of
upstream pro-apoptotic signaling events, which are frequently
deregulated in many cancers and which become resistant to most
classical anti-cancer agents that target upstream regulators of
MOMP (Fulda et al., 2010). Because of this convergence of apop-
totic signaling on the MOMP, anti-cancer drugs that directly
target the MPTP could have the potential to bypass the resis-
tance mechanisms of cancer. Therefore, better understanding at
a molecular composition of the MPTP will provide clues for
effective and selective therapeutic strategies for the treatment of
cancer. Further studies are warranted to elucidate the mechanism
of MOMP through the MPTP.
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